Related references
Note: Only part of the references are listed.2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary
Jennifer S. Lawton et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial
Doyeon Hwang et al.
JAMA CARDIOLOGY (2022)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
A sex paradox in clinical outcomes following complex percutaneous coronary intervention
Johny Nicolas et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues
Robert F. Storey
HEART (2021)
Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy Introduction
Filippo Crea
EUROPEAN HEART JOURNAL (2021)
Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease The EXCEL Trial
Gennaro Giustino et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials
Eliano P. Navarese et al.
CIRCULATION (2020)
Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients The ISAR-REACT 5 Trial
Katharina Mayer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry)
Umair Khalid et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Deepak L. Bhatt et al.
LANCET (2019)
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
S. Schuepke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016
Elias J. Dayoub et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2019)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Standardized End Point Definitions for Coronary Intervention Trials
Hector M. Garcia-Garcia et al.
EUROPEAN HEART JOURNAL (2018)
Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients
Tullio Palmerini et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor
Zuzana Motovska et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Real-World Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
Cynthia Larmore et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Prasugrel Monitoring and Bleeding in Real World Patients
Guillaume Cayla et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome
Thomas Cuisset et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Third Universal Definition of Myocardial Infarction
Kristian Thygesen et al.
CIRCULATION (2012)
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James et al.
EUROPEAN HEART JOURNAL (2010)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study
Paul A. Gurbel et al.
CIRCULATION (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)